Immunotherapy plus chemo shows promise for rare lung cancer
NCT ID NCT05470595
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy (platinum and etoposide) can help people with advanced large-cell neuroendocrine lung cancer live longer. About 67 participants who have not had prior systemic treatment will receive the combination for four cycles, followed by atezolizumab alone. The study measures overall survival, tumor response, and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (an immunotherapy drug) combined with standard chemotherapy (platinum and etoposide)
What this could lead to
If successful, this could offer a new, more effective treatment option for people with advanced large-cell neuroendocrine lung cancer, potentially improving survival and disease control.
What could go wrong
This is a mid-stage trial with only 67 participants and no comparison group, so results may not be definitive. Immunotherapy can cause immune-related side effects, and the cancer may still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asklepios Fachkliniken München-Gauting
Gauting, 82131, Germany
-
Charité - Universitätsklinikum Berlin Centrum 12, Medizinische Klinik
Berlin, 10117, Germany
-
Evangelische Lungenklinik
Berlin, 12125, Germany
-
Klinikum der J.W. Goethe Universität, Medizinische Klinik II
Frankfurt am Main, 60590, Germany
-
Klinikum der Johannes Gutenberg Universität, III. Med. Klinik und Poliklinik
Mainz, 55131, Germany
-
Klinikum der Universität zu Köln, Klinik I für Innere Medizin
Cologne, 50937, Germany
-
Krankenhaus St. Elisabeth und St. Barbara Halle (Saale) GmbH
Halle, 06110, Germany
-
LungenClinic Grosshansdorf GmbH
Großhansdorf, 22927, Germany
-
Lungenfachklinik Immenhausen
Immenhausen, 34376, Germany
-
Lungenklinik Hemer des Deutschen Gemeinschafts-Diakonieverbandes GmbH
Hemer, 58675, Germany
-
Pius Hospital, Klinik für Hämatologie und Onkologie
Oldenburg, 26121, Germany
-
Rems-Murr-Klinikum Winnenden, Klinik für Hämatologie, Onkologie und Palliativmedizin
Winnenden, 71364, Germany
-
Robert-Bosch-Krankenhaus GmbH
Stuttgart, 70376, Germany
-
Thoraxklinik Heidelberg gGmbH, Universitätsklinikum Heidelberg
Heidelberg, 69126, Germany
-
Universitätsklinikum Dresden, Medizinische Klinik 1
Dresden, 01307, Germany